While non-selective β-blockers, which counteract pathological neovascularization, have a clear rationale for use during the proliferative phase of ROP, when pathological angiogenesis is already initiated (16), the timing for β3-AR agonist treatment remains less well defined. This evidence concerns the gene ADRB3 and retinopathy of prematurity.